This morning the Honorable Barbara Mikulski (D-Md), a strong advocate for biomedical research funding, announced that she will retire from Congress at the end of her term in 2016.

This week the American Board of Internal Medicine (ABIM) announced needed changes to its Maintenance of Certification (MOC) program, specifically placing a temporary suspension on the Practice Assessment requirement and freezing MOC enrollment fees through 2017.

Amid the growing debate about the high price of powerful new drugs in the United States, a recent analysis suggests that breakthrough therapies for blood cancers may, in many cases and with some important caveats, provide reasonable value for money spent. Researchers present this viewpoint, based upon a comprehensive analysis of published cost-effectiveness ratios, online today in Blood, the Journal of the American Society of Hematology (ASH).